Email this article Adipogenic Differentiation of Human Mesenchymal Stem Cells Derived from Fetal Bone Marrow Using Rosiglitazone
- Authors: Revittser A.V.1, Neguliaev Y.A.1,2
-
Affiliations:
- Department of Medical Physics, Peter the Great St. Petersburg Polytechnic University
- Institute of Cytology, Russian Academy of Sciences
- Issue: Vol 12, No 5 (2018)
- Pages: 367-372
- Section: Article
- URL: https://journals.rcsi.science/1990-519X/article/view/212745
- DOI: https://doi.org/10.1134/S1990519X18050061
- ID: 212745
Cite item
Open Access
Access granted
Subscription Access
Abstract
Protocols of adipogenic differentiation for mesenchymal stem cells (MSC) are mostly based on addition of various inducers, including rosiglitazone, a. specific agonist of PPARG facilitated the differentiation in this lineage. Rosiglitazone was not used for induction of adipogenic differentiation of fetal MSC from bone marrow (fMSC-BM). Here we described adipogenic differentiation induced by rosiglitazone in fMSC-BM (FetMSC). We found that the number of differentiated cells was 31.0 ± 1.9% (Oil Red O staining n = 1121). Expression of PPARG gene, a key adipogenic regulator, increased during differentiation. It is demonstrated that fMSC-BM generated adipocytes in the differentiation medium with rosiglitazone.
About the authors
A. V. Revittser
Department of Medical Physics, Peter the Great St. Petersburg Polytechnic University
Author for correspondence.
Email: eetytnet@gmail.com
Russian Federation, St. Petersburg, 195251
Yu. A. Neguliaev
Department of Medical Physics, Peter the Great St. Petersburg Polytechnic University; Institute of Cytology, Russian Academy of Sciences
Email: eetytnet@gmail.com
Russian Federation, St. Petersburg, 195251; St. Petersburg, 194064
